Pneumocystis Jirovecii Pneumonia in Non-HIV-infected Immunocompromised Patients

Pneumocystis Jirovecii Infection Clinical Trial

— PnP-HIV-Free  

Official title:

Pneumocystis Jirovecii Pneumonia in Non-HIV-infected Immunocompromised Patients : a Prognostic Observational Retrospective Monocentre Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05458752
• Other study ID #: 2020PI184-Pre-existing datas
• Status: Completed
• Start date: April 1, 2020
• Est. completion date: July 1, 2023

Study information

• Verified date: July 2023
• Source: Central Hospital, Nancy, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Pneumocystis jirovecii pneumonia (PjP) is a rare infectiouse disease with a high level of mortality. PjP is a classical opportunistic infection which concern HIV infected and immunocompromised patients. During the past decade, several therapeutic's progresses have been done in oncology, immunology and hematology. As a consequence, patients benefited of greater treatment efficacy but are exposed to a higher risk of opportunistic infections as PjP. The investigators hypothesis is that PjP incidence increase and its form is depending of underlying immune conditions. The investigators aim to describe its incidence, the PjP forms depending on comorbidities and to identifiy pronostics factors.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 133
• Est. completion date: July 1, 2023
• Est. primary completion date: June 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Underlying immune condition at risk of Pneumocystis jirovecii pneumonia excluding HIV infection

• Clinical, biological and radiological presentation which evoke Pneumocystis jirovecii pneumonia

• Microbiological confirmation by respiratory specimen analyses ( specific coloration and/or IFI and/or PRC)

Exclusion Criteria:

• No microbiological confirmation by respiratory specimen analyses

• Proved HIV infection

• Patient denied to particpate

Related Conditions & MeSH terms

• Pneumocystis Infections
• Pneumocystis Jirovecii Infection
• Pneumonia
• Pneumonia, Pneumocystis

Locations

Country	Name	City	State
France	Université de Lorraine, CHRU Nancy and APEMAC	Vandoeuvre Les Nancy	Lorraine

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Pneumocystis jirovecii pneumonia in HIV-free patients	Number of cases / number of patients treated for a predisposing disease (heamotological or imunological disease, or cancer...)	Between the first january 2004 and the 31th december 2021
Secondary	To describe the age of giv free patients with Pneumocystis jirovecci pneumonia	age in years	Between the first january 2004 and the 31th december 2021
Secondary	To describe the body mass index of HIV free patients with Pneumocystis jirovecci pneumonia	BMI in kg/m2 (quanti	Between the first january 2004 and the 31th december 2021
Secondary	To describe the Charlson comorbidity index of HIV free patients with Pneumocystis jirovecci pneumonia	Charlson comorbidity index as a quantitative variable	Between the first january 2004 and the 31th december 2021
Secondary	To describe the comoribidites of HIV-free patients with Pneumocystis jirovecci pneumonia	Comorbidities as categorial variables	Between the first january 2004 and the 31th december 2021
Secondary	To describe the previous medications used by HIV free patients with Pneumocystis jirovecci pneumonia	Medications as categorial variables	Between the first january 2004 and the 31th december 2021
Secondary	To describe clinical features of Pneumocystis jirovecci pneumonia in HIV-free patients	Type of first symptoms as categorial variables	Between the first january 2004 and the 31th december 2021
Secondary	To describe the date of the first symptoms of Pneumocystis jirovecci pneumonia in HIV-free patients	Date of first symptoms as quantitative variable	Between the first january 2004 and the 31th december 2021
Secondary	To describe the pO2 level of HIV free patients with Pneumocystis jirovecci pneumonia	pO2 (in mmHg)	Between the first january 2004 and the 31th december 2021
Secondary	To describe the PCR level of HIV free patients with Pneumocystis jirovecci pneumonia	PCR (mg/L)	Between the first january 2004 and the 31th december 2021
Secondary	To describe the WBC level of HIV free patients with Pneumocystis jirovecci pneumonia	WBC (G/L)	Between the first january 2004 and the 31th december 2021
Secondary	To describe the creatinine level of HIV free patients with Pneumocystis jirovecci pneumonia	Creatinine (µmol/L)	Between the first january 2004 and the 31th december 2021
Secondary	To describe the LDH level of HIV free patients with Pneumocystis jirovecci pneumonia	LDH (MUI/L)	Between the first january 2004 and the 31th december 2021
Secondary	To describe the albumin level of HIV free patients with Pneumocystis jirovecci pneumonia	albumin (g/L)	Between the first january 2004 and the 31th december 2021
Secondary	To describe the immunoglobulin level of HIV free patients with Pneumocystis jirovecci pneumonia	immunoglobulin (g/L)	Between the first january 2004 and the 31th december 2021
Secondary	To describe the lymphocytes level of HIV free patients with Pneumocystis jirovecci pneumonia	lymphocytes (G/L)	Between the first january 2004 and the 31th december 2021
Secondary	To describe the PCR pneumocystis level of HIV free patients with Pneumocystis jirovecci pneumonia	PCR pneumocystis in ct	Between the first january 2004 and the 31th december 2021
Secondary	To describe the immunofluorescence value of HIV free patients with Pneumocystis jirovecci pneumonia	Immunofluorescence as a categorial variable	Between the first january 2004 and the 31th december 2021
Secondary	To describe the specific coloration value of HIV free patients with Pneumocystis jirovecci pneumonia	Specific coloration as a categorial variable	Between the first january 2004 and the 31th december 2021
Secondary	To describe the use of nasal canula in HIV free patient with a Pneumocystis jirovecci pneumonia	Nasal canula as a categorial variable	Between the first january 2004 and the 31th december 2021
Secondary	To describe the use of high flow oxygenation in HIV free patient with a Pneumocystis jirovecci pneumonia	High flow oxygenation as a categorial variable	Between the first january 2004 and the 31th december 2021
Secondary	To describe the use of mechanical ventilation in HIV free patient with a Pneumocystis jirovecci pneumonia	Mechanical ventilation as a categorial variable	Between the first january 2004 and the 31th december 2021
Secondary	To describe the duration of hospitalisation of HIV free patients with Pneumocystis carinii pneumonia	Duration in days	Between the first january 2004 and the 31th december 2021
Secondary	To describe the use of cotrimoxazole for HIV free patients with Pneumocystis carinii pneumonia	cotrimoxazole as a categorial variable	Between the first january 2004 and the 31th december 2021
Secondary	To describe the use of atovaquone for HIV free patients with Pneumocystis carinii pneumonia	atovaquone as a categorial variable	Between the first january 2004 and the 31th december 2021
Secondary	To describe the use of pentamidine for HIV free patients with Pneumocystis carinii pneumonia	pentamidine as a categorial variable	Between the first january 2004 and the 31th december 2021
Secondary	To describe the use of steroïd for HIV free patients with Pneumocystis carinii pneumonia	steroïd as a categorial variable	Between the first january 2004 and the 31th december 2021